therapeutic action: Posaconazole (antifungal)

Detection and diagnostic process of liver abscess secondary to chemotherapy by mucor indicus in a patient with acute leukemic disease: case report

mycolabadmin

A 60-year-old man with acute leukemia developed a serious fungal infection in his liver caused by Mucor indicus after receiving chemotherapy that weakened his immune system. Doctors identified the infection through tissue samples and genetic testing, then treated him successfully with antifungal medications amphotericin B and posaconazole. This case highlights the importance of early detection and proper diagnosis of rare fungal infections in cancer patients undergoing chemotherapy.

Read More »

Invasive Rhinocerebral Mucormycosis Is a Rare Complication in Systemic Juvenile Idiopathic Arthritis Patient

mycolabadmin

A 5-year-old girl with systemic juvenile arthritis being treated with immunosuppressive medications developed a rare and serious fungal infection in her nose and sinuses caused by a mold called Lichtheimia. The infection caused tissue death and spread toward her brain, but was successfully treated with combination antifungal drugs and surgery. This case highlights how powerful immunosuppressive treatments for severe arthritis can increase the risk of life-threatening fungal infections.

Read More »

A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori

mycolabadmin

Scientists developed a new way to test antifungal drugs using silkworms instead of expensive and ethically problematic mammal studies. They infected silkworms with mucormycosis-causing fungi and found that the infections behaved similarly to human cases, especially when they simulated human risk factors like steroid use and iron overload. The silkworm model successfully demonstrated that existing antifungal drugs work, while also revealing differences in fungal virulence that were linked to specific surface proteins.

Read More »
Scroll to Top